New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically

被引:77
作者
Boyer, James L. [1 ]
机构
[1] Yale Univ, Sch Med, Liver Ctr, New Haven, CT 06520 USA
关键词
FARNESOID-X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; BILE-SALT TRANSPORTERS; HEPATIC STELLATE CELLS; VITAMIN-D-RECEPTOR; URSODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID; NUCLEAR RECEPTORS; OBSTRUCTIVE CHOLESTASIS; HEPATOBILIARY TRANSPORT;
D O I
10.1016/j.jhep.2006.12.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The molecular basis of the bile formation and the adaptive responses that are known to occur in cholestatic liver injury is discussed. Current and possible future therapies for jaundice and cholestasis that are mediated by nuclear receptor ligands are also discussed. Cholestasis is a clinical syndrome that results from the disturbances in the formation of bile, a unique and vital property of liver. Steps in bile formation and metabolism can be divided into the four phases of hepatic uptake, hydroxylation, conjugation, and excretion. Adaptive responses are insufficient to prevent cholestasis from developing leading to up-regulation of several other transporters at the sinusoidal surface of the liver. Nuclear receptor medicine is being used to treat certain patients with cholestasis liver disease based on current knowledge of the diverse effects of nuclear receptor ligands and activators on bile acid metabolism and bile acid transporters.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 78 条
[51]   Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans [J].
Marschall, HU ;
Wagner, M ;
Zollner, G ;
Fickert, P ;
Diczfalusy, U ;
Gumhold, J ;
Silbert, D ;
Fuchsbichler, A ;
Benthin, L ;
Grundström, R ;
Gustafsson, U ;
Sahlin, S ;
Einarsson, C ;
Trauner, M .
GASTROENTEROLOGY, 2005, 129 (02) :476-485
[52]   Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid [J].
Parés, A ;
Caballería, L ;
Rodés, J .
GASTROENTEROLOGY, 2006, 130 (03) :715-720
[53]   Hepatocellular transporters and cholestasis [J].
Pauli-Magnus, C ;
Meier, PJ .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (04) :S103-S110
[54]   Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets [J].
Paumgartner, Gustav .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (28) :4445-4451
[55]   6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity [J].
Pellicciari, R ;
Fiorucci, S ;
Camaioni, E ;
Clerici, C ;
Costantino, G ;
Maloney, PR ;
Morelli, A ;
Parks, DJ ;
Willson, TM .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3569-3572
[56]   Farnesoid X receptor regulates bile acid-amino acid conjugation [J].
Pircher, PC ;
Kitto, JL ;
Petrowski, ML ;
Tangirala, RK ;
Bischoff, ED ;
Schulman, IG ;
Westin, SK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (30) :27703-27711
[57]  
RIZ O, 2006, IN PRESS J BIOL CHEM
[58]  
Rizzo Giovanni, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P289, DOI 10.2174/1568008054863781
[59]  
RLOANTA JJ, 2005, METHOD ENZYMOL, V400, P511
[60]   MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis [J].
Rosmorduc, O ;
Hermelin, B ;
Poupon, R .
GASTROENTEROLOGY, 2001, 120 (06) :1459-1467